Drug
Angeliq
Angeliq: highest development phase Phase 3, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| Angeliq (Drospirenone/17ß-estradiol, BAY86-4891) NCT00102141 | Phase 3 | Hypertension |
Latest
No recent events.
Follow Angeliq on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.